Technical Analysis for CERC - Cerecor Inc.

Grade Last Price % Change Price Change
grade A 5.1 3.03% 0.15
CERC closed up 3.03 percent on Friday, January 18, 2019, on approximately normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
4 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical CERC trend table...

Date Alert Name Type % Chg
Jan 18 Upper Bollinger Band Walk Strength 0.00%
Jan 18 Inside Day Range Contraction 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Above Upper BB Strength 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 18 Upper Bollinger Band Touch Strength 0.00%
Jan 17 Calm After Storm Range Contraction 3.03%
Jan 17 Wide Range Bar Range Expansion 3.03%
Jan 17 Upper Bollinger Band Walk Strength 3.03%
Jan 17 Outside Day Range Expansion 3.03%

Older signals for CERC ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Analyze My Stocks!
Configure default chart indicators
Basic chart:
Profile
Cerecor, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs for the treatment of patients with neurological and psychiatric disorders. The company has a portfolio of clinical and preclinical compounds, such as CERC-301, CERC-501, and CERC-406. It develops CERC-301 that is in Phase II development stage as an oral, adjunctive antidepressant for the treatment of patients with major depressive disorder (MDD); CERC-501, which is in Phase II development, for co-occurring psychiatric and substance use disorders; and CERC-406 that is its preclinical lead candidate that inhibit catechol-O-methyltransferase within the brain, as well as anticipates developing CERC-406 for the treatment of residual cognitive impairment symptoms in patients with MDD. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor, Inc. was founded in 2011 and is headquartered in Baltimore, Maryland.
Is CERC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Jan 16 FDA Grants Cerecor’s Three Substrate Replacement Therapies Orphan Drug Designation
Jan 15 FDA tags three Cerecor candidates Orphan Drugs; shares up 2%
Dec 13 Antares Pharma Announces the Appointment of Peter S. Greenleaf to Company’s Board of Directors
Nov 28 Cerecor (CERC) Presents At Piper Jaffray 30th Annual Healthcare Conference - Slideshow
Nov 26 CERC: Unveils Rare Pediatric Disease Programs…
Nov 22 What Kind Of Share Price Volatility Should You Expect For Cerecor Inc (NASDAQ:CERC)?
Nov 21 Analysis: Positioning to Benefit within KemPharm, Bellerophon Therapeutics, Exela Technologies, Intec Pharma, Cerecor, and Chiasma — Research Highlights Growth, Revenue, and Consolidated Results
Nov 13 Cerecor misses by $0.59, misses on revenue
Nov 13 Cerecor Reports Third Quarter 2018 Results
Oct 31 Cerecor Announces Submission of Three Orphan Drug Designation Requests for Substrate Replacement Therapies to treat Congenital Disorders of Glycosylation
See more CERC news...
Indicators
Indicator Value
52 Week High 5.74
52 Week Low 2.71
Average Volume 69,380
200-Day Moving Average 4.1749
50-Day Moving Average 3.6698
20-Day Moving Average 3.73
10-Day Moving Average 4.217
Average True Range 0.3735
ADX 31.43
+DI 28.937
-DI 8.8582
Chandelier Exit (Long, 3 ATRs ) 4.0795
Chandelier Exit (Short, 3 ATRs ) 3.8305
Upper Bollinger Band 4.9987
Lower Bollinger Band 2.4613
Percent B (%b) 1.04
BandWidth 68.02681
MACD Line 0.3475
MACD Signal Line 0.1558
MACD Histogram 0.1917
Fundamentals Value
Market Cap 132.86 Million
Num Shares 26.1 Million
EPS -1.12
Price-to-Earnings (P/E) Ratio -4.55
Price-to-Sales 24.44
Price-to-Book 4.41
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.02
Resistance 3 (R3) 5.93 5.52 5.87
Resistance 2 (R2) 5.52 5.29 5.57 5.82
Resistance 1 (R1) 5.31 5.14 5.42 5.41 5.77
Pivot Point 4.91 4.91 4.96 4.95 4.91
Support 1 (S1) 4.70 4.67 4.80 4.79 4.43
Support 2 (S2) 4.29 4.52 4.34 4.38
Support 3 (S3) 4.08 4.29 4.33
Support 4 (S4) 4.18